{"id":"https://openalex.org/W2108350814","doi":null,"title":"Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.","display_name":"Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.","publication_year":2000,"publication_date":"2000-07-01","ids":{"openalex":"https://openalex.org/W2108350814","mag":"2108350814","pmid":"https://pubmed.ncbi.nlm.nih.gov/10914705"},"language":"en","primary_location":{"id":"pmid:10914705","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10914705","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial"},"volume":null,"type":"article","indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"T A Davis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"T A Davis","raw_affiliation_strings":["Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland 20852, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland 20852, USA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016684714","display_name":"David G. Maloney","orcid":"https://orcid.org/0000-0002-8477-6919","observed_orcids":["https://orcid.org/0000-0002-8477-6919"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D G Maloney","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110185143","display_name":"A.J. Grillo-L\u00f3pez","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A J Grillo-L\u00f3pez","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103576806","display_name":"Christine A. White","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C A White","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068317734","display_name":"Mechelle Williams","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M E Williams","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001607309","display_name":"George J. Weiner","orcid":"https://orcid.org/0000-0003-3427-0562","observed_orcids":["https://orcid.org/0000-0003-3427-0562"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G J Weiner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110300852","display_name":"Scot D. Dowden","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S Dowden","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5083342021","display_name":"Ronald Levy","orcid":"https://orcid.org/0000-0003-2061-0650","observed_orcids":["https://orcid.org/0000-0003-2061-0650"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R Levy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":7.1836,"has_fulltext":false,"cited_by_count":120,"citation_normalized_percentile":{"value":0.97609192,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"6","issue":"7","first_page":"2644","last_page":"52"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0017999999690800905,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.9850000143051147},{"id":"https://openalex.org/keywords/interferon-alfa-2a","display_name":"interferon alfa-2a","score":0.9929999709129333},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.9290000200271606},{"id":"https://openalex.org/keywords/low-grade-b-cell-lymphoma","display_name":"low-grade B-cell lymphoma","score":0.824999988079071},{"id":"https://openalex.org/keywords/follicular-lymphoma","display_name":"follicular lymphoma","score":0.9769999980926514},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6340000033378601},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.746999979019165},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.8539999723434448}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9155795574188232},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.8344502449035645},{"id":"https://openalex.org/C2778594517","wikidata":"https://www.wikidata.org/wiki/Q2260058","display_name":"Chills","level":2,"score":0.8080998659133911},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6420080065727234},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.6277862787246704},{"id":"https://openalex.org/C2778616394","wikidata":"https://www.wikidata.org/wiki/Q474959","display_name":"myalgia","level":2,"score":0.6045013070106506},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.6033933162689209},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5952809453010559},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5829272270202637},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.5764092206954956},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.524286687374115},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5171348452568054},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.4458499550819397},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4216909110546112},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.39192765951156616},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.376675546169281},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.21827617287635803},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.15502336621284485},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069283","descriptor_name":"Rituximab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007167","descriptor_name":"Immunotherapy","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008224","descriptor_name":"Lymphoma, Follicular","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008224","descriptor_name":"Lymphoma, Follicular","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016393","descriptor_name":"Lymphoma, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016393","descriptor_name":"Lymphoma, B-Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058846","descriptor_name":"Antibodies, Monoclonal, Murine-Derived","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:10914705","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10914705","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial"},{"id":"mag:2108350814","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10914705","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":41,"referenced_works":["https://openalex.org/W60759546","https://openalex.org/W111063158","https://openalex.org/W206701898","https://openalex.org/W1484629663","https://openalex.org/W1501418793","https://openalex.org/W1514217221","https://openalex.org/W1533050051","https://openalex.org/W1545320152","https://openalex.org/W1599654455","https://openalex.org/W1880104048","https://openalex.org/W1912693401","https://openalex.org/W1915689252","https://openalex.org/W1942869033","https://openalex.org/W1945274657","https://openalex.org/W1992964537","https://openalex.org/W2005027156","https://openalex.org/W2022285897","https://openalex.org/W2042578248","https://openalex.org/W2054049748","https://openalex.org/W2056847748","https://openalex.org/W2068776651","https://openalex.org/W2081543802","https://openalex.org/W2086940701","https://openalex.org/W2104940816","https://openalex.org/W2110422885","https://openalex.org/W2112476236","https://openalex.org/W2150728688","https://openalex.org/W2155001516","https://openalex.org/W2158277472","https://openalex.org/W2168054545","https://openalex.org/W2168926834","https://openalex.org/W2179208207","https://openalex.org/W2182845139","https://openalex.org/W2267583049","https://openalex.org/W2302140131","https://openalex.org/W2325085632","https://openalex.org/W2328311363","https://openalex.org/W2409710975","https://openalex.org/W2419170672","https://openalex.org/W2471197104","https://openalex.org/W2471620674"],"related_works":["https://openalex.org/W2168508518","https://openalex.org/W7018010892","https://openalex.org/W2268917628","https://openalex.org/W2317176902","https://openalex.org/W2150728688","https://openalex.org/W2472330091","https://openalex.org/W2418864820","https://openalex.org/W2944087014","https://openalex.org/W2165172574","https://openalex.org/W2035469650"],"abstract_inverted_index":{"Rituximab":[0],"and":[1,27,34,92,179,199,213,223],"IFN":[2],"have":[3],"each":[4],"demonstrated":[5],"single-agent":[6,246],"activity":[7],"in":[8,36,219],"patients":[9,38,85,99],"with":[10,32,39,135,248],"low-grade":[11,43],"non-Hodgkin's":[12],"lymphoma":[13],"(NHL).":[14],"A":[15],"single-arm,":[16],"multicenter,":[17],"Phase":[18],"II":[19],"trial":[20],"was":[21,55,72,114,131,188],"conducted":[22],"to":[23,217,231,238,243],"assess":[24],"the":[25,66,117,141,154,209,214],"safety":[26],"efficacy":[28],"of":[29,69,90,106,111,160,165,169,173,177,182,191],"combination":[30,142,236],"therapy":[31],"rituximab":[33,71,91],"IFN-alpha-2a":[35,48,112],"38":[37,84,161,192],"relapsed":[40],"or":[41,44,50],"refractory,":[42],"follicular,":[45],"B-cell":[46],"NHL.":[47],"[2.5":[49],"5":[51],"million":[52],"units":[53,120],"(MIU)]":[54],"administered":[56,73],"s.c.,":[57],"three":[58],"times":[59],"weekly":[60,79],"for":[61,80,95,208],"12":[62],"weeks.":[63],"Starting":[64],"on":[65],"fifth":[67],"week":[68],"treatment,":[70],"by":[74],"i.v.":[75],"infusion":[76],"(375":[77],"mg/m2)":[78],"4":[81,146],"doses.":[82],"All":[83],"received":[86,121],"four":[87],"complete":[88,197],"infusions":[89],"were":[93,122,148],"evaluable":[94],"efficacy,":[96],"although":[97],"11":[98],"(29%)":[100],"did":[101],"not-receive":[102],"all":[103],"36":[104],"injections":[105,113],"IFN.":[107],"The":[108,128,184,205],"mean":[109,118],"number":[110],"31":[115],"doses;":[116],"total":[119],"141":[123],"MIU":[124],"(maximum,":[125],"180":[126],"MIU).":[127],"study":[129],"treatment":[130,155,235,247],"reasonably":[132],"well":[133],"tolerated":[134],"no":[136],"unexpected":[137],"toxicities":[138],"stemming":[139],"from":[140],"therapy.":[143],"No":[144],"grade":[145],"events":[147,152],"reported.":[149],"Frequent":[150],"adverse":[151],"during":[153],"period":[156],"included":[157],"asthenia":[158],"(35":[159],"patients),":[162],"chills":[163],"(31":[164],"38),":[166,170,174,178],"fever":[167],"(30":[168],"headache":[171],"(28":[172],"nausea":[175],"(23":[176],"myalgia":[180],"(22":[181],"38).":[183],"overall":[185],"response":[186,211],"rate":[187],"45%":[189],"(17":[190],"patients);":[193],"11%":[194],"had":[195,201],"a":[196,202,239],"response,":[198],"34%":[200],"partial":[203],"response.":[204],"Kaplan-Meier":[206],"estimates":[207],"median":[210,215],"duration":[212],"time":[216,242],"progression":[218,244],"responders":[220],"are":[221],"22.3":[222],"25.2":[224],"months,":[225],"respectively.":[226],"Further":[227],"follow-up":[228],"is":[229],"needed":[230],"determine":[232],"whether":[233],"this":[234],"leads":[237],"significantly":[240],"longer":[241],"than":[245],"rituximab.":[249]},"counts_by_year":[{"year":2021,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}